XBRAF:OTC-Xebra Brands Ltd (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.0363

Change

+0.01 (+27.82)%

Market Cap

USD 2.98M

Volume

0.03M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-27 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MKGAF MERCK Kommanditgesellschaft au..

-1.13 (-0.85%)

USD 58.42B
MKKGY Merck KGaA ADR

+0.51 (+1.96%)

USD 56.10B
HLNCF Haleon plc

-0.01 (-0.09%)

USD 50.12B
TKPHF Takeda Pharmaceutical Co. Ltd.

N/A

USD 46.97B
TEVJF Teva Pharmaceutical Industries..

N/A

USD 20.77B
HNSPF Hansoh Pharmaceutical Group Co..

N/A

USD 20.51B
SDZNY Sandoz Group AG

-0.04 (-0.08%)

USD 19.79B
SDZXF Sandoz Group AG

N/A

USD 17.55B
SWOBY Swedish Orphan Biovitrum AB (p..

N/A

USD 10.30B
IPSEY Ipsen SA ADR

+0.10 (+0.33%)

USD 9.48B

ETFs Containing XBRAF

XSE:CA iShares Conservative Stra.. 8.93 % 0.56 %

+0.06 (+0.42%)

CAD 0.11B
XSI:CA iShares Short Term Strate.. 2.98 % 0.56 %

+0.07 (+0.42%)

CAD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 118.67% 95% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 118.67% 95% A 93% A
Trailing 12 Months  
Capital Gain -48.14% 49% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.14% 49% F 22% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.40% 65% D 54% F
Dividend Return 6.40% 64% D 50% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 176.13% 22% F 22% F
Risk Adjusted Return 3.63% 63% D 42% F
Market Capitalization 2.98M 52% F 28% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector